UNLIMITED TURBO LONG - IPSEN | Market Closed - Euronext Paris 10:00:02 27/06/2024 pm IST | ||
| 0.785 EUR | -3.68% |
|
| Current month | -30.80% | ||
| 1 month | -30.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IPSEN
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 0.785 | -3.68% |
| 26/24/26 | 0.815 | -5.78% |
| 25/24/25 | 0.865 | -4.42% |
| 24/24/24 | 0.905 | +18.30% |
| 21/24/21 | 0.765 | -15.47% |
Real-time Euronext Paris
Last update June 27, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | IPSEN |
| Issuer | 
BNP Paribas
|
| 0X3IB | |
| ISIN | FRBNPP04USR7 |
| Date issued | 27/09/2022 |
| Strike | 100.3 € |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.845 € |
|---|---|
| Lowest since issue | 0.105 € |
Company Profile
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
-
Consensus: Ipsen
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
114.8
EUR
Average target price
127.3
EUR
Spread / Average Target
+10.87%
- Stock Market
- Certificates
- 0X3IB Certificat
